Vitamin B12 is essential for DNA synthesis, myelin formation, and one-carbon metabolism, yet a striking proportion of Indians — estimated at 47–70% of adults — have clinically low circulating B12 levels even when their diets are not severely restricted. Part of this disparity has a genetic explanation: a regulatory variant near the FUT6 gene that subtly suppresses fucosyltransferase¹¹ fucosyltransferase
An enzyme that attaches fucose sugar molecules to glycoproteins and glycolipids, influencing cell-surface signalling and microbial interactions activity and, through that, lowers circulating B12.

The Mechanism

FUT6 encodes alpha-(1,3)-fucosyltransferase 6, a Golgi enzyme that synthesises sialyl-Lewis X²² sialyl-Lewis X
A carbohydrate structure on cell surfaces that serves as a ligand for E-selectin and controls cell-cell adhesion, immune trafficking, and gut microbial colonisation glycan structures. These fucosylated glycans line the intestinal epithelium and serve as a biological interface between host cells and gut microbiota.

rs3760775 sits in a regulatory region near the FUT6 promoter/enhancer cluster on chromosome 19p13.3. The G allele (the common allele in Europeans, the risk allele here) is associated with lower FUT6 expression, while the T allele preserves higher expression. The companion variant rs78060698 at the same locus has been shown through luciferase reporter assays and electrophoretic mobility shift assays to exhibit allele-specific promoter and enhancer activity, affecting binding of HNF4α³³ HNF4α
Hepatocyte Nuclear Factor 4α — a transcription factor that regulates expression of multiple fucosyltransferases and is highly expressed in the gut and liver, a key regulator of fucosyltransferase expression in the gut.

The functional pathway linking FUT6 to B12 most likely runs through two routes: first, altered intestinal fucosylation changes the gut microbiome composition, affecting microbial B12 synthesis and uptake; second, fucosylation of haptocorrin⁴⁴ haptocorrin
Also called transcobalamin I — a glycoprotein that binds ~80% of circulating B12 but is metabolically inert; only the liver can extract B12 from it, the dominant B12-binding protein in serum, may affect its hepatic clearance rate, altering how much B12 remains in circulation.

The Evidence

The primary evidence comes from a 2017 GWAS by Nongmaithem et al.⁵⁵ Nongmaithem et al.
Nongmaithem SS et al. GWAS identifies population-specific new regulatory variants in FUT6 associated with plasma B12 concentrations in Indians. Hum Mol Genet, 2017 conducted in 1,001 healthy participants from the Pune Maternal Nutrition Study with replication in 3,418 Indians from independent cohorts (total n = 4,419). The T allele at rs3760775 was associated with higher B12 levels at genome-wide significance (meta-analysis beta = 0.25, P = 1.2×10⁻²³ on log-transformed B12). The effect allele frequency was 0.27 in Indians versus only 0.06 in Europeans (CEU), indicating the variant and its population impact are substantially higher in South Asians.

Conditional analysis showed that rs3760775 captures the primary signal at this locus, with rs3760776 and rs78060698 tagging the same or overlapping signals in the FUT6 region. The association was replicated consistently across sex, age, pregnancy status, and ethnicity subgroups.

A large PLOS Genetics meta-analysis⁶⁶ PLOS Genetics meta-analysis
Grarup N et al. Genetic Architecture of Vitamin B12 and Folate Levels Uncovered Applying Deeply Sequenced Large Datasets. PLoS Genet, 2013 confirmed the FUT6/FUT3 cluster as one of 11 B12-associated loci across European and Icelandic populations. All identified loci together explain about 6.3% of B12 variance, consistent with polygenic architecture.

The mechanism was further illuminated by studies of the related FUT2 gene: Rogne et al. 2017⁷⁷ Rogne et al. 2017
Rogne S et al. FUT2 secretor variant p.Trp154Ter influences serum vitamin B12 concentration via holo-haptocorrin. Hum Mol Genet, 2017 demonstrated that FUT2 non-secretors have 16–22% higher total B12 but unchanged active B12 (holo-transcobalamin), because fucosylation affects haptocorrin glycosylation and hepatic clearance, not intestinal uptake per se. A similar mechanism likely operates at FUT6 — meaning the effect on total circulating B12 is real, but the clinically relevant fraction (active B12 delivered to tissues) may differ from what total serum B12 tests show.

Practical Actions

If you carry two G alleles at rs3760775 (GG), your FUT6 expression is likely somewhat lower, reducing the fucosylation-dependent mechanisms that support B12 metabolism. Given that Indians already have high background rates of B12 deficiency partly explained by vegetarian diets, this genetic variant can compound dietary inadequacy. The most direct action is to ensure adequate B12 intake and to use the most bioavailable supplemental forms when needed.

For monitoring: serum total B12 may not fully reflect cellular B12 status when fucosylation-dependent haptocorrin clearance is altered. Holo-transcobalamin (active B12) or methylmalonic acid (MMA) testing provides a more accurate picture of functional B12 sufficiency.

Interactions

FUT6 rs3760775 acts additively with FUT2 rs601338 and rs602662 — both affect fucosylation in overlapping pathways. Carrying risk alleles at multiple FUT loci compounds the effect on B12 regulation. Additionally, B12 metabolism intersects with the folate-methylation cycle: low B12 elevates homocysteine, which in turn amplifies risks from MTHFR C677T (rs1801133) heterozygosity. The FUT3-FUT5-FUT6 gene cluster on 19p13.3 shows distinct linkage disequilibrium patterns across ethnicities, which is why this variant's impact is most pronounced in South Asian populations.

Nuclear factor kappa B (NF-κB) is the master transcription factor of the human inflammatory response. Every time your immune cells detect a pathogen, sense tissue damage, or respond to cytokine signals, NF-κB activates within minutes — switching on hundreds of target genes for cytokines, chemokines, adhesion molecules, and antimicrobial peptides. The NFKB1 gene encodes p105 and p50, the two critical NF-κB subunits that both drive and regulate this response. rs3774937 is a common intronic variant in NFKB1 that has emerged from large-scale genomic studies as a genuine susceptibility locus for chronic inflammatory disease — reaching genome-wide significance across ulcerative colitis and a pleiotropic analysis of five distinct immune-mediated conditions.

The Mechanism

rs3774937 lies within an intron of NFKB1 at chromosome 4 position 102,513,096 (GRCh38) and does not alter the p105 or p50 protein sequence. Intronic variants can nonetheless influence gene function through several mechanisms: altering splicing enhancer or silencer sequences¹¹ splicing enhancer or silencer sequences
Intronic regulatory elements that guide which exons are included in the final mRNA transcript, modifying transcription factor binding sites embedded within introns, or marking linkage disequilibrium²² linkage disequilibrium
Non-random co-inheritance of alleles at nearby loci; rs3774937 may tag a causal functional variant at the NFKB1 locus without being directly causal itself with a functional variant that has not yet been fully characterized. The nearby rs28362491 variant — a four-nucleotide ATTG insertion-deletion in the NFKB1 5' regulatory region with documented effects on promoter activity — is the most likely functional candidate at this chromosomal location; rs3774937 has been included in NFKB1 haplotype analyses alongside rs28362491, rs230521, rs230510, and rs4648068, suggesting they tag overlapping regulatory variation.

The biological consequence of reduced NF-κB1 p50 activity is a shift in the immune inflammatory set point. The p50 homodimer acts as a transcriptional repressor of pro-inflammatory genes — it competes with the activating p50/p65 heterodimer for DNA binding at NF-κB response elements. Reduced p50 protein means less of this negative feedback, resulting in higher baseline cytokine production and exaggerated inflammatory responses to immune triggers. This mechanism connects reduced NFKB1 transcriptional activity to the observed associations with conditions driven by chronic or dysregulated inflammation.

The Evidence

The strongest evidence comes from genome-wide association studies of inflammatory bowel disease. Liu et al. (2015)³³ Liu et al. (2015)
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature Genetics. — a trans-ancestry meta-analysis — identified rs3774937 at the NFKB1 locus with genome-wide significance for ulcerative colitis (OR approximately 1.10, p=5×10⁻¹⁴, risk allele frequency 0.33 in the discovery cohort). The modest odds ratio paired with extreme statistical significance across tens of thousands of samples confirms this is a robust genetic association.

Ellinghaus et al. (2016)⁴⁴ Ellinghaus et al. (2016)
Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nature Genetics. conducted a pleiotropy analysis in over 86,000 European-ancestry individuals across ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, and ulcerative colitis. The NFKB1 locus (tagged by rs3774937) reached p=2×10⁻¹⁸ in the cross-disease analysis — among the most significant signals in the entire study. This pleiotropic signal indicates that the same regulatory variation at NFKB1 contributes to multiple distinct immune-mediated conditions, consistent with NF-κB1's role as a central node in immune homeostasis rather than a disease-specific factor.

Beyond IBD and autoimmune phenotypes, Cabrera et al. (2014)⁵⁵ Cabrera et al. (2014)
Intronic variants in the NFKB1 gene may influence hearing forecast in patients with unilateral sensorineural hearing loss in Menière's disease. PLoS One. reported that rs3774937 C allele carriers with unilateral Menière's disease reach hearing stage 3 (greater than 40 dB loss) significantly faster than non-carriers (p=0.009, log-rank corrected). The study enrolled 716 Menière's disease cases and 1,628 controls — the association was specific to unilateral disease, consistent with an inflammatory component in the inner ear lesion driven by NF-κB1 pathway variation.

In the transplant setting, Kuba et al. (2020)⁶⁶ Kuba et al. (2020)
NFKB1 gene single-nucleotide polymorphisms: implications for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Annals of Hematology. reported strong association of rs3774937 genotype with acute graft-versus-host disease in 109 transplant recipients — evidence that the variant influences post-transplant immune responses, where NF-κB signaling governs allogeneic T cell activation and cytokine production.

Practical Actions

The per-allele OR of approximately 1.10 for ulcerative colitis and similarly modest effect sizes for other conditions mean that rs3774937 does not determine disease fate — it tilts the immune landscape modestly in the direction of dysregulated inflammatory signaling. For CC homozygotes (~9% of Europeans), two copies compound this tilt. The actionable consequence is proactive monitoring of inflammatory burden and support for the NF-κB regulatory mechanisms this locus influences.

Monitoring circulating biomarkers of systemic inflammation — particularly high-sensitivity CRP (hsCRP) and calprotectin if gastrointestinal symptoms arise — provides direct insight into whether this genetic signal is translating into detectable inflammatory activity in the individual. Omega-3 fatty acids at therapeutic doses reduce NF-κB activation and downstream cytokine production through resolvin and protectin pathways that directly intersect with the NF-κB signaling axis.

Interactions

rs3774937 sits within the same NFKB1 genomic region as several other variants studied in this encyclopedia: rs28362491 (the -94ATTG functional indel in the NFKB1 5' regulatory region, associated with cardiovascular and autoimmune risk), rs230523 (intronic NFKB1 variant associated with infection susceptibility), and rs4648127 (a rare protective intronic variant associated with reduced lung cancer risk). These variants are in partial linkage disequilibrium and may partly tag the same causal signal — users who carry risk alleles at multiple NFKB1 intronic positions should treat their combined signal with caution to avoid double-counting the same underlying regulatory effect.

TLR4 (rs4986790) and TLR1 (rs5743708) variants acting upstream of NF-κB activation may compound with NFKB1 variants to produce additive reductions in pathogen-driven immune gene expression when both receptor-level and transcription-factor-level variation co-occur.

Psoriasis is not a single disease driven by a single pathway — it is the collision of two inflammatory cascades: the NF-kB signaling axis¹¹ NF-kB signaling axis
NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a master transcription factor that controls genes for TNF-α, IL-1β, IL-6, and many other pro-inflammatory cytokines; it is the primary driver of the keratinocyte hyperproliferation and immune cell recruitment seen in psoriatic plaques and the type I interferon axis²² type I interferon axis
Type I interferons (IFN-α and IFN-β) are signaling proteins produced by plasmacytoid dendritic cells and keratinocytes that amplify innate immune responses; they are particularly prominent in early psoriasis lesions and plaque initiation. The gene IKBKE encodes IKK-epsilon (IKKε)³³ IKK-epsilon (IKKε)
Inhibitor of NF-kB kinase subunit epsilon — a serine/threonine kinase related to canonical IKKα and IKKβ but with distinct substrates and a unique position at the crossroads of innate antiviral and inflammatory signaling, a kinase that sits at the intersection of both pathways and governs the amplitude of both responses simultaneously. The rs41298997 intronic variant in IKBKE was identified in the largest psoriasis GWAS to date as a novel, genome-wide-significant susceptibility locus, with the T allele conferring a modest but statistically robust increase in psoriasis risk.

The Mechanism

IKKε operates at a hub where three signaling pathways converge. First, it phosphorylates IRF3 and IRF7⁴⁴ IRF3 and IRF7
Interferon regulatory factors 3 and 7 — transcription factors that, once phosphorylated by IKKε or its homolog TBK1, undergo conformational change, dimerize, and translocate to the nucleus to activate IFN-β and IFN-α gene transcription; this is the primary amplifier of the antiviral and early innate immune response, driving type I interferon production. Second, IKKε phosphorylates inhibitors of NF-kB (IkBs), freeing the NF-kB complex to translocate to the nucleus and switch on pro-inflammatory cytokine genes including TNF-α, IL-1β, and IL-6. Third, IKKε phosphorylates STAT1 at serine-708⁵⁵ STAT1 at serine-708
This phosphorylation selectively promotes assembly of the ISGF3 complex (STAT1:STAT2:IRF9) over GAF (STAT1 homodimer) formation; ISGF3 drives interferon-stimulated gene expression while GAF drives a different transcriptional program; IKKε thus acts as a molecular switch that shapes which arm of the interferon response dominates, tuning the balance between type I and type II interferon-driven transcriptional programs.

The rs41298997 variant lies within an intron of IKBKE and is presumed to influence gene expression or splicing rather than protein structure, although the exact regulatory mechanism has not been characterized at the molecular level. Its location at 1q32.1 — a chromosomal region enriched for immune regulatory elements — and the genome-wide significance of its association with psoriasis places it in the same functional class as other regulatory psoriasis loci that modulate pathway-level signaling intensity rather than abolishing it.

The Evidence

The primary evidence comes from the Tsoi et al. 2017 meta-analysis⁶⁶ Tsoi et al. 2017 meta-analysis
Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nature Communications, 2017. Combined effective sample size >39,000 individuals across eight Caucasian cohorts., which identified 16 novel genome-wide-significant psoriasis loci. The rs41298997-T allele reached genome-wide significance (OR=1.13, p=2.37×10⁻⁸) with a risk allele frequency of approximately 19% in cases versus 18% in controls — a small but consistent enrichment across tens of thousands of individuals. The study performed pathway analysis showing that genes at novel loci, including IKBKE, clustered in the "Regulation of I-kB kinase/NF-kB cascade" pathway (11 associated loci) and in T-cell regulatory elements, confirming the biological relevance of the association.

The molecular role of IKKε was established by two mechanistic studies. Fitzgerald et al. 2003⁷⁷ Fitzgerald et al. 2003
Fitzgerald KA et al., IKKε and TBK1 are essential components of the IRF3 signaling pathway. Nature Immunology 2003. demonstrated that IKKε and TBK1 together are required for IRF3-mediated IFN-β induction in response to viral signals, placing IKKε as an essential gatekeeper of innate antiviral immunity. Ng et al. 2011⁸⁸ Ng et al. 2011
Ng SL et al., IκB kinase ε (IKKε) regulates the balance between type I and type II interferon responses. PNAS 2011. then showed that IKKε does not merely activate interferons but actively shapes which interferon-driven transcriptome is expressed by determining whether ISGF3 or GAF forms — a distinction with profound implications for whether cells respond in an antiviral versus inflammatory mode.

The OR of 1.13 per T allele is modest by Mendelian disease standards but is consistent with the polygenic architecture of psoriasis, where dozens of loci each contribute small effects that combine to produce the 60–80% heritability of the disease. The T allele frequency is notably higher in East Asian populations (~61%) compared to Europeans (~24%) and Africans (~18%), which may contribute to differences in psoriasis prevalence and phenotype across ancestries.

Practical Implications

For CT heterozygotes and TT homozygotes, the most actionable implication is awareness: psoriasis tends to develop in genetically predisposed individuals following environmental triggers — streptococcal throat infections, mechanical skin trauma (Koebner phenomenon), certain medications (lithium, beta-blockers, antimalarials, rapid steroid withdrawal), and psychological stress. Recognizing early plaque formation and seeking dermatological evaluation promptly improves outcomes significantly.

The IKBKE locus is of particular interest for therapy: IKKε inhibition has been investigated as a therapeutic strategy in inflammatory disease, and IKKε's dual role in NF-kB and interferon signaling means that dysregulation at this node may influence both the initiating events (interferon-driven plasmacytoid dendritic cell activation) and the sustaining events (NF-kB-driven keratinocyte hyperproliferation and cytokine amplification) in psoriasis pathogenesis. While no IKKε-targeted therapy is currently approved for psoriasis, existing biologics that block downstream cytokines (anti-IL-17, anti-IL-23, anti-TNF) all target effectors downstream of the NF-kB pathway that IKBKE feeds into.

Interactions

IKBKE functionally interacts with STAT4 (rs7574865) in psoriasis susceptibility: STAT4 is activated by IL-12 and IL-23 downstream of the NF-kB pathway that IKKε activates. Individuals carrying risk alleles at both loci may have amplified Th1/Th17 polarization, as IKKε drives the upstream cytokine milieu (via IFN and NF-kB signaling) while STAT4 determines how sensitively T cells respond to those cytokines. This interaction has not been formally tested in psoriasis but parallels the well-documented IRF5–STAT4 interaction in lupus susceptibility.

The IKBKE-encoded kinase also functions within a complex containing TBK1 and scaffold proteins including TANK, NAP1, and SINTBAD. Variants affecting other members of this kinase complex (TBK1 variants) may compound with rs41298997 to amplify innate immune signaling, though no interaction data specific to psoriasis yet exist.

The melanocortin-4 receptor (MC4R) gene sits at the center of your brain's appetite control system. Located in the hypothalamus¹¹ hypothalamus
the brain region governing hunger, satiety, and energy balance, MC4R receives signals from leptin and melanocortin hormones to generate "stop eating" commands. The stretch of chromosome 18 roughly 188 kilobases downstream of MC4R contains a regulatory haplotype block — a cluster of variants inherited together — that controls how much MC4R your neurons produce. rs476828 sits within this block.

This SNP tags the same obesity-associated haplotype as the better-known rs17782313, the second strongest common obesity genetic signal in humans²² second strongest common obesity genetic signal in humans
after FTO rs9939609. In Europeans, rs476828 and rs17782313 are in perfect linkage disequilibrium³³ perfect linkage disequilibrium
r²=1 in the CEU HapMap sample, meaning the two variants are essentially interchangeable as markers for the same underlying haplotype. In African-ancestry populations the LD is weaker (r²=0.526), meaning rs476828 carries some independent information there. Together with rs12970134, these three variants form the risk haplotype C–C–A, which carries OR=1.796 for obesity.

The Mechanism

rs476828 is an intergenic variant in a regulatory element⁴⁴ regulatory element
a stretch of DNA that controls gene transcription without encoding protein itself that modulates MC4R expression in hypothalamic neurons. The full signaling chain works as follows: fat cells secrete leptin⁵⁵ leptin
a hormone that reports energy stores to the brain, which activates POMC neurons⁶⁶ POMC neurons
proopiomelanocortin neurons in the arcuate nucleus that generate appetite-suppressing signals, which release alpha-melanocyte stimulating hormone (α-MSH), which binds MC4R. When MC4R fires, it suppresses appetite and increases energy expenditure. When regulatory variants reduce MC4R expression, this entire cascade is weakened — fewer receptors means quieter "stop eating" signals and reduced metabolic drive.

The C allele of rs476828 tags a haplotype associated with reduced MC4R promoter activity. Epigenetic studies⁷⁷ Epigenetic studies
MeQTL analyses examining DNA methylation quantitative trait loci show that this regulatory block is associated with increased MC4R promoter methylation, further suppressing expression. The net result is a hypothalamic satiety circuit that requires stronger signals to fire — meaning larger portions before fullness registers, and a higher baseline appetite drive.

The Evidence

The original landmark GWAS⁸⁸ landmark GWAS
Loos et al., Nature Genetics 2008, n=16,876 discovery + 60,352 replication identified this MC4R-region signal as the second strongest common BMI locus in humans. Per C allele, adults showed a 0.05 Z-score BMI increase (p=2.8×10⁻¹⁵); children aged 7–11 showed a larger 0.13 Z-score effect (p=1.5×10⁻⁸), and severe childhood obesity odds reached OR=1.30 (p=8.0×10⁻¹¹). rs476828 was directly studied in a childhood obesity cohort⁹⁹ childhood obesity cohort
Grant et al., 728 obese European American children and 3,960 controls and yielded OR=1.145 (p=0.042), consistent with its role as a perfect proxy for rs17782313 in European-ancestry individuals.

A 2020 haplotype study¹⁰¹⁰ 2020 haplotype study
Wei et al., Mol Med, 1,836 Chinese participants examined rs476828 directly and found the C allele significantly elevated in obesity cases versus controls (17.1% vs 10.9%, p<0.001), with a dominant-model OR of 1.585 (95% CI=1.176–2.136). The full C–C–A haplotype across rs17782313, rs476828, and rs12970134 yielded OR=1.796 (95% CI=1.447–2.229), illustrating that these three markers collectively tag a single high-risk regulatory configuration.

A prospective cohort study in 5,724 women¹¹¹¹ prospective cohort study in 5,724 women
Qi et al., Hum Mol Genet 2008 found that this MC4R locus (tagged by rs17782313) was associated with higher total energy and dietary fat intake, greater 10-year BMI gain, and 14% increased type 2 diabetes risk per C allele after BMI adjustment — indicating effects on metabolic regulation beyond adiposity alone.

A sex-specific layer was uncovered by neuroimaging in 284 adults¹²¹² neuroimaging in 284 adults
Horstmann et al., PLoS One 2013: female homozygous CC carriers showed increased gray matter volume in the right amygdala, hippocampus, and orbitofrontal cortex — regions encoding emotional memory and food reward — as well as significantly elevated disinhibition and emotional eating scores. These effects were absent in men, suggesting the MC4R regulatory haplotype has sex-specific impacts on the neural circuits governing food motivation.

Practical Implications

Carrying the C allele at rs476828 means your hypothalamic MC4R system operates with reduced receptor density. Satiety signals that would normally be sufficient to stop eating are muted — your brain requires more food intake before the "full" signal reaches threshold. This creates a persistent biological headwind for weight management, but one that responds well to strategies that compensate for weakened internal signals with external structure.

The fat and energy intake data from the women's cohort are particularly actionable: the genetic effect operates partly through appetite drive for energy-dense foods. Interventions that reduce the palatability and caloric density of available food (meal preparation at home, portion pre-commitment, structured eating environments) directly address the mechanism.

The sex-specific neuroimaging data suggest that women with CC genotype may benefit especially from interventions targeting emotional and reward-driven eating, since this is where the documented brain structural differences concentrate.

Interactions

rs17782313 and rs12970134: rs476828 sits in the same regulatory block as these two MC4R-region variants. In Europeans, rs476828 and rs17782313 are in perfect LD (r²=1) — they are interchangeable markers for the same haplotype. The three-SNP haplotype C–C–A (rs17782313–rs476828–rs12970134) carries the highest obesity risk (OR=1.796), while individual SNP effects are smaller. Carrying risk alleles at all three does not simply stack independent risks; they largely reflect the same underlying regulatory signal.

FTO rs9939609: The combined effect¹³¹³ combined effect
documented across multiple populations of MC4R and FTO risk alleles exceeds either alone — MC4R acts through appetite suppression while FTO acts through thermogenesis, so the two pathways are partially independent and their effects add. Combined risk genotypes in one pediatric study conferred 2.45-fold increased obesity odds. Addressing both pathways simultaneously — appetite structure for MC4R, thermogenic activity for FTO — provides complementary benefit.

On chromosome 19 at band q13.42, within a dense cluster of reproductive-aging loci, lies a variant that has drawn attention for its unexpectedly large effect on early menopause risk. The rs4806660 SNP falls within the gene TMEM150B — also known as DRAM3 (Damage-Regulated Autophagy Modulator 3) — a transmembrane protein expressed in oocytes whose precise role in reproductive aging is still being worked out.

A note on gene attribution: early GWAS publications initially assigned this locus to the nearby BRSK1 gene (also at 19q13.42) based on physical proximity. Subsequent fine-mapping established that rs4806660 and the lead SNP rs1172822 are in near-complete linkage disequilibrium (R²=0.965) and both fall within the TMEM150B gene body. Some older references still label this locus as BRSK1 or "ZNF346" (a chromosome 5 gene unrelated to this locus); the current consensus assigns it to TMEM150B.

The Mechanism

TMEM150B encodes a five-transmembrane-domain protein that belongs to the DRAM family¹¹ DRAM family
Damage-Regulated Autophagy Modulators — a class of lysosomal and endosomal membrane proteins that regulate autophagic flux under conditions of cellular stress. The protein localises to lysosomes, endosomes, and the plasma membrane. Overexpression studies show that TMEM150B promotes autophagosome accumulation and enhances autophagic flux under baseline conditions; it also promotes cell survival during glucose deprivation through an autophagy-independent mechanism.

Autophagy²² Autophagy
the cellular self-digestion pathway that recycles damaged organelles and proteins to maintain oocyte quality is increasingly recognised as a critical maintenance system in the dormant oocyte pool. Human oocytes are arrested for decades; their long-term viability depends on continuous quality-control mechanisms to handle accumulated protein aggregates and dysfunctional mitochondria. Defective autophagy in granulosa cells and oocytes has been linked to accelerated follicular atresia and POI in animal models.

rs4806660 is an intronic variant, meaning it does not alter the protein sequence. The most likely mechanism is cis-regulatory³³ cis-regulatory
affecting the expression level of a nearby gene rather than its protein sequence: the C allele may alter TMEM150B expression in ovarian cells in ways that subtly compromise the autophagy-mediated quality control sustaining the follicle pool. However, the precise regulatory effect of this specific intronic change on TMEM150B expression in human ovarian tissue has not yet been directly characterised.

It is important to note that when Tmem150b was completely knocked out in mice, female fertility was normal and hormone levels were unchanged⁴⁴ female fertility was normal and hormone levels were unchanged
Liu et al. 2020, Scientific Reports. This may indicate functional redundancy within the DRAM family, species differences in the specific gene's requirement, or that the effect of the common human intronic variant operates through a mechanism distinct from complete gene ablation.

The Evidence

The 19q13.42 locus was first identified by Stolk et al. 2009⁵⁵ Stolk et al. 2009
Loci at chromosomes 13, 19 and 20 influence age at natural menopause. Nature Genetics, 2009 in a two-stage GWAS of 2,979 European women (Rotterdam Study and TwinsUK), with the lead SNP rs1172822 reaching p = 6.3 × 10⁻¹¹. Subsequent fine-mapping using imputed data identified rs4806660 as an additional SNP in the same LD block with even stronger statistical support.

The most informative study for clinical interpretation is the Breakthrough Generations Study⁶⁶ Breakthrough Generations Study
Murray et al. 2011, Human Molecular Genetics, ~2,000 women with early menopause before age 46 versus controls. In this case-control design, each C allele was associated with an odds ratio of 1.45 (95% CI 1.32–1.59, p = 8.88 × 10⁻¹⁶) for experiencing menopause before age 46. Notably, the observed odds ratio was substantially larger than the 1.20 expected from quantitative trait estimates — suggesting a non-linear effect where the C allele may have a disproportionate impact on the earliest end of the menopause-age distribution, affecting those most biologically susceptible to early follicular depletion.

Beyond menopause timing, a Brazilian IVF cohort study by Setti et al. 2012⁷⁷ Setti et al. 2012
A chromosome 19 locus positively influences the number of retrieved oocytes during stimulated cycles in Brazilian women. Journal of Assisted Reproduction and Genetics, 2012 found that women carrying the T allele (the protective/common allele) had significantly more antral follicles (+2.54 per cycle, P=0.041) and more retrieved oocytes (+1.41 per cycle, P=0.041) during controlled ovarian stimulation — providing a direct, clinically measurable link between this variant and the functional ovarian reserve available for IVF.

A Mashhad cohort study 2021⁸⁸ Mashhad cohort study 2021
Genetic Determinants of Premature Menopause in a Mashhad Population Cohort. IJFS, 2021 found that the C allele in Iranian women was associated with premature menopause risk (OR 3.09, 95% CI 1.17–8.16 in a recessive model), though this did not survive Bonferroni correction. The direction of effect is consistent with European data, suggesting the association may generalise across Middle Eastern populations, but effect sizes remain uncertain outside the original European GWAS context.

Population differences are striking: the C allele is common in Europeans (~36%), African-ancestry (~37%), and South Asian (~41%) populations, but is found at substantially lower frequency in East Asian populations (~8%). This means the variant's contribution to population-level menopause timing variation is much smaller in East Asian women.

Practical Actions

For women with the common TT genotype, this variant suggests a somewhat lower genetic load for early follicular depletion at this locus. AMH testing remains the most direct measure of current reserve and is appropriate for fertility planning regardless of genotype.

For C allele carriers, the primary implication is a modestly elevated probability of earlier reproductive aging — a probabilistic shift, not a certainty. The variant may be particularly relevant when ovarian response to gonadotropin stimulation is lower than expected, since Setti et al. suggest this locus influences the gonadotropin-responsive follicle pool.

Interactions

TMEM150B rs4806660 + MCM8 rs16991615 (19q13.42 + 20p12.3 menopause loci): MCM8 rs16991615 (E341K, DNA repair helicase) is among the most robustly replicated menopause-timing loci with an effect of approximately 1 year per A allele. Women carrying the common risk GG genotype at MCM8 (absent protective allele) who also carry one or two C alleles at rs4806660 accumulate two independent additive hits on follicular reserve through distinct biological pathways — DNA repair and autophagy regulation. A compound action for this combination emphasising early AMH baseline testing and proactive reproductive timeline discussion is warranted.

TMEM150B rs4806660 + PRRC2A rs1046089 (immune-linked menopause locus): rs1046089 in the HLA-region PRRC2A gene acts through immune modulation of follicular atresia. Combined C allele burden at rs4806660 alongside the A allele at rs1046089 converges on reproductive aging through two further independent mechanisms (autophagy dysregulation and immune-mediated follicle depletion). Women with risk alleles at both loci may benefit from earlier fertility assessment than either variant alone would indicate.

The AGTR1 gene¹¹ AGTR1 gene
encodes the angiotensin II type 1 receptor, a critical component of the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure, fluid balance, and cardiovascular function. The A1166C variant (rs5186) is the most well-studied AGTR1 SNP, located in the 3′ untranslated region . While it doesn't change the protein sequence directly, it may affect mRNA stability and transcription, or be in linkage disequilibrium with another polymorphism of regulatory significance .

The Mechanism

This variant sits in the 3' UTR²² 3' UTR
the untranslated region after the protein-coding sequence where regulatory elements control gene expression.

The AGTR1 A1166C polymorphism may influence the stability of mRNA expression and might be involved in cellular signaling mediated by the angiotensin II receptor . Some studies have found that the C allele is associated with reduced AGTR1 mRNA levels — 0.8-fold lower in heterozygotes and 0.27-fold lower in homozygotes compared to AA carriers , though findings are inconsistent across studies.

The AT1 receptor mediates the effects of angiotensin II, causing vasoconstriction, sodium retention, increased blood pressure, and activation of inflammatory pathways. The receptor is the target of ARBs³³ ARBs
angiotensin receptor blockers, a class of blood pressure medications including losartan, valsartan, candesartan, and irbesartan.

The Evidence

The relationship between rs5186 and hypertension has been extensively studied but remains controversial.

A systematic review and meta-analysis of AGTR1 polymorphisms and hypertension found that the literature is too heterogeneous to draw meaningful conclusions , with insufficient evidence that polymorphisms in the AGTR1 gene are risk factors for hypertension . However, specific populations and conditions show clearer associations.

For cardiovascular outcomes⁴⁴ For cardiovascular outcomes, a meta-analysis of 53 studies with 20,435 CHD cases and 23,674 controls found only a weak association between A1166C and coronary heart disease, likely due to publication bias and heterogeneity . In contrast, the rs5186 polymorphism significantly increases the risk of restenosis after percutaneous coronary intervention (PCI) in Asian populations .

For metabolic conditions⁵⁵ For metabolic conditions, the gain-of-function rs5186 A1166C variant has been linked to hypertension, cardiovascular disease, and metabolic syndrome .

The variant affects liver disease, insulin resistance, and endothelial dysfunction in NAFLD, at least in part by modulating adipokine, chemokine, and pro-inflammatory cell activation in response to fat ingestion .

For kidney health⁶⁶ For kidney health, the C allele shows an odds ratio of 1.84 for diabetic nephropathy in Iranian patients , and shows a likelihood ratio of 1.89-2.01 for GFR depletion in type 2 diabetes patients .

For brain health⁷⁷ For brain health,

C1166 variant carriers show significantly larger subcortical hyperintensity volume compared to AA genotype carriers in healthy older adults , suggesting the C1166 variant may serve as a biomarker of risk for suboptimal brain integrity prior to changes in cognition .

Practical Implications

The primary clinical relevance of rs5186 is in predicting response to ARB medications.

Individuals with the AC genotype show significant reduction in systolic blood pressure after candesartan medication in Chinese populations .

The percentage of systolic BP reduction with candesartan-based treatment was greater in patients with AC genotypes compared to AA homozygotes .

However, carrying the 1166C allele is associated with greater compensatory increase in renin activity and more modest effect on aldosterone after candesartan treatment , suggesting long-term RAAS activation that may affect clinical outcomes.

The variant also has implications beyond blood pressure. Given its associations with metabolic syndrome, NAFLD, diabetic nephropathy, and cerebrovascular changes, C allele carriers may benefit from closer monitoring of metabolic health, kidney function, and cardiovascular risk factors — particularly if they have diabetes or metabolic syndrome.

Interactions

AGTR1 rs5186 functions as part of the renin-angiotensin-aldosterone system pathway. It may interact with other RAAS-related SNPs including ACE I/D (rs4340), which affects angiotensin-converting enzyme activity and modifies response to ACE inhibitors, and AGT M235T (rs699), which influences angiotensinogen levels and blood pressure. Studies suggest that individuals with multiple RAAS pathway variants show cumulative effects on hypertension risk and treatment response. The variant's effects may also be modified by CYP2C9 polymorphisms, particularly for ARBs metabolized by this enzyme like losartan and irbesartan.

Your immune cells depend on a precisely organized cell membrane to function. The outer leaflet of every immune cell membrane is kept nearly free of phosphatidylserine — a lipid that, when exposed on the surface, signals "eat me" to phagocytes and dampens T-cell activation. A family of proteins called P4-ATPases (phospholipid flippases) does this housekeeping work, pumping phosphatidylserine¹¹ phosphatidylserine
A negatively charged phospholipid that is normally sequestered on the inner face of the plasma membrane; when it flips to the outer leaflet, it triggers apoptosis recognition and dampens immune signaling from the outer leaflet back inside. ATP8B4 is one of these flippases, expressed at especially high levels in bone marrow and immune-relevant tissues. The rs55687265 variant — a C allele on the plus strand creating the amino acid change Phe436Leu in the protein's transmembrane transport domain — appears to compromise this pumping activity, with measurable consequences for autoimmune disease risk.

The Mechanism

ATP8B4 belongs to the P4-type ATPase subfamily (also called type IV ATPases or phospholipid flippases). These enzymes use ATP hydrolysis to flip specific phospholipids from the outer to the inner leaflet of cellular membranes — maintaining the lipid asymmetry that is fundamental to healthy cell signaling. Disruption of this asymmetry in immune cells alters how those cells interpret and transmit inflammatory signals. In dendritic cells and macrophages, improper phosphatidylserine distribution on the plasma membrane affects toll-like receptor clustering²² toll-like receptor clustering
TLRs are pattern-recognition receptors that initiate innate immune responses; their signaling efficiency depends partly on local membrane lipid composition and downstream NF-kB activation dynamics.

The F436L substitution replaces a phenylalanine with a leucine in the transmembrane transport domain of the enzyme. Phenylalanine at this position is conserved across P4-ATPase family members and is predicted to participate in the phospholipid-binding pocket's geometry. Changing it to leucine — a smaller, less aromatic residue — is predicted to reduce substrate affinity or transport rate. Differential expression³³ Differential expression
SSc patients showed significantly altered ATP8B4 transcript levels compared to controls (P = 0.0005), consistent with a functional role in disease of ATP8B4 was observed between SSc patients and controls at the mRNA level, supporting biological involvement beyond just the genetic association.

The Evidence

The primary evidence comes from a whole-exome sequencing study⁴⁴ whole-exome sequencing study
WES sequences the protein-coding regions of the genome; rare variant burden analyses aggregate low-frequency variants by gene to detect associations too rare to find with single-SNP tests by Gao et al. (2016, Arthritis & Rheumatology, PMID 26473621) that performed gene-level burden analysis in European-American systemic sclerosis patients with and without pulmonary arterial hypertension. The rs55687265 variant emerged as the single strongest association signal within ATP8B4 — discovery cohort P = 9.35 × 10⁻¹⁰, OR 6.11. Replication in 415 SSc cases and 2,848 controls yielded OR 1.86 (P = 0.012). Meta-analysis across both cohorts: OR 2.5 (P = 1.92 × 10⁻⁷). Gene-level burden for all ATP8B4 rare variants reached P = 2.77 × 10⁻⁷.

A subsequent analysis by López-Isac et al.⁵⁵ López-Isac et al.
A multi-center European consortium follow-up study examining the F436L variant in an independent Spanish, Italian, German, and Dutch SSc cohort (2017, PMID 28141915) specifically assessed rs55687265 in a larger European-American SSc population. ATP8B4 gene-level burden was also detected in African American SSc patients⁶⁶ African American SSc patients
Whole-exome sequencing in 148 African American SSc cases and 2,397 controls; ATP8B4 among enriched genes (Gourh et al., 2018, PMID 29732714), extending the biological signal beyond European ancestry.

In parallel, a landmark Nature Genetics exome study⁷⁷ Nature Genetics exome study
16,036 Alzheimer's disease cases and 16,522 controls; gene-level burden test using SKAT-O across all rare damaging variants per gene (Holstege et al., 2022, PMID 36411364) of 32,558 individuals identified rare damaging variants across ATP8B4 as a significant Alzheimer's disease risk gene — placing it alongside TREM2, SORL1, and ABCA1 as genes involved in lipid membrane homeostasis in brain tissue, particularly in microglia.

The evidence across systemic sclerosis and Alzheimer's disease points to a shared mechanism: defective phospholipid flipping in immune cells (peripheral in SSc, central microglia in Alzheimer's) disrupts membrane lipid asymmetry, alters phagocytic and inflammatory signaling, and ultimately increases susceptibility to chronic dysregulated inflammation.

Practical Actions

The C allele at rs55687265 is rare globally (~1.4% overall, ~1.5% in Europeans, essentially absent in East Asians). Most carriers will be heterozygous GC. The elevated OR from the discovery cohort (OR 6.11) may reflect ascertainment bias from a highly selected SSc-with-PAH enriched sample; the replication OR of 1.86 and meta-analytic OR of 2.5 are better estimates of effect size in the general population. This is a meaningful but not deterministic risk factor — the C allele raises susceptibility, it does not guarantee disease.

Given the phospholipid transport mechanism, interventions that support membrane lipid composition and reduce chronic immune activation are most relevant. Omega-3 fatty acids (EPA/DHA) directly incorporate into immune cell membranes, modifying the pool of lipid substrates that flippases act on. Antioxidants that protect phospholipids from oxidation — particularly astaxanthin and vitamin E — reduce the load of oxidatively damaged phospholipids that accumulate when flipping is impaired.

Interactions

ATP8B4 belongs to the same P4-ATPase family as ATP8B1 (expressed in hepatocytes and bile ducts) and ATP8B2. The biological overlap with ABCA1 is particularly notable — ABCA1 is another lipid transporter independently identified as an Alzheimer's disease risk gene in the same Holstege et al. study, and both genes participate in cholesterol and phospholipid homeostasis in macrophages and microglia. Carriers of risk variants in both ATP8B4 and ABCA1 may face compounding lipid transport defects in immune cells, though no published compound analysis exists yet for this pair.

Systemic sclerosis as a disease involves dysregulated fibrotic and vascular responses alongside immune activation. Established SSc risk loci include rs2476601 (PTPN22), rs3087243 (CTLA4), and rs6920220 (TNFAIP3), which operate through T-cell and B-cell regulation rather than membrane lipid transport. ATP8B4 represents a distinct biological pathway into SSc susceptibility.

LD Redundancy Flag

IMPORTANT NOTE FOR REVIEW: rs6165 (Ala307Thr) and rs6166 (Asn680Ser) are in near-complete linkage disequilibrium. Published studies report D'=0.997 and r²=0.82–0.99 across populations¹¹ Published studies report D'=0.997 and r²=0.82–0.99 across populations
Vietnamese cohort study, 2025: OR=490 for sharing the same genotype between the two SNPs. The two variants form a fixed haplotype in most populations: Ala307-Ser680 (CC at rs6165, GG at rs6166) is the reduced-sensitivity haplotype; Thr307-Asn680 (TT at rs6165, AA at rs6166) is the high-sensitivity haplotype. Because r² exceeds 0.80, rs6165 may be informationally redundant with rs6166 for most clinical purposes. The key question for platform inclusion is whether the Ala307Thr amino acid change provides independent mechanistic information beyond Asn680Ser. Current evidence suggests it does — the extracellular glycosylation mechanism is distinct — but genotypically these SNPs rarely differ in real-world data. This entry is maintained for completeness and for users whose genome file happens to include one but not the other.

The Extracellular Hinge Variant That Shapes How FSH Binds Its Receptor

The FSH receptor (FSHR) is a glycoprotein with a large extracellular domain that captures circulating FSH, and an intracellular signaling domain that converts FSH binding into cAMP production. While rs6166 (Asn680Ser) sits in the intracellular domain and alters the kinetics of cAMP signaling, rs6165 affects an entirely different part of the receptor. The Ala307Thr substitution is located in the [hinge region²² The Ala307Thr substitution is located in the [hinge region
The region connecting the leucine-rich repeat domain to the transmembrane domain] of the extracellular domain.

The Mechanism

The Ala307Thr change (coding strand G→A, representing threonine substituting for alanine at position 307) introduces a threonine residue where alanine previously sat. Critically, this substitution removes a potential [O-linked glycosylation site | A site where sugar chains can be added to the protein, altering its stability, folding, and binding properties]. Glycosylation at this position is thought to influence FSH binding affinity directly — the Ala307 variant (the ancestral form, encoded by the coding-strand G allele, which appears as C in genome files due to the minus-strand orientation of the FSHR gene) lacks this glycosylation site, while Thr307 carries it.

The consequence is that the Ala307 haplotype is associated with altered FSH affinity in the extracellular domain³³ Ala307 haplotype is associated with altered FSH affinity in the extracellular domain
Complementing the intracellular kinetic changes caused by the linked rs6166 Ser680 variant. In practice, because these two variants are almost always inherited together, it is difficult to distinguish their independent contributions clinically. What is consistent is that the Ala307-Ser680 haplotype (CC at rs6165 plus GG at rs6166 in plus-strand notation) is associated with reduced FSH receptor sensitivity overall — an effect attributable to both the extracellular binding change (Ala307Thr) and the intracellular signaling change (Asn680Ser) acting in concert.

The Evidence

The most direct evidence for rs6165 specifically comes from a 2025 study of 79 Vietnamese women with diminished ovarian reserve⁴⁴ 2025 study of 79 Vietnamese women with diminished ovarian reserve
Hoang et al. Applied Clinical Genetics, 2025. Women with the GG genotype at rs6165 (coding notation: Ala/Ala) retrieved significantly fewer total oocytes (4.63 vs 5.73, p=0.04), showed lower follicular output rate (FORT) and follicular oocyte index (FOI), and were 490 times more likely to also carry the GG genotype at rs6166 (p<0.0001) — confirming the near-complete haplotype structure.

A 2024 systematic review and meta-analysis⁵⁵ 2024 systematic review and meta-analysis
Association of FSHR gene polymorphisms with poor ovarian response in patients undergoing IVF, Gene 2024 covering 6 studies and 444 POR cases versus 875 controls found that the T allele of rs6165 (Thr307, which carries the glycosylation site) is associated with higher POR risk in Caucasian populations: T vs C allelic OR=1.64 (95% CI 1.25–2.16); homozygous TT vs CC OR=2.76 (95% CI 1.43–5.32). Note: this result — where the Thr allele (T on plus strand) associates with poor response — appears to contrast with some haplotype data, and may reflect population-specific allele frequency differences or heterogeneity across studies. The biological interpretation remains that the Ala307-Ser680 haplotype overall associates with reduced FSH sensitivity, even where individual allele OR directions vary across studies.

A 2024 multicenter prospective study across Europe and Asia⁶⁶ 2024 multicenter prospective study across Europe and Asia
The Additive Effect of Combinations of FSH Receptor Gene Variants in Ovarian Response to Stimulation, Reproductive Sciences 2024 examining diplotypes found that the rs6165/rs6166 AG/AG combination was associated with more hypo-response (33.1% vs 24.0%, adjOR 1.77, 95% CI 1.08–2.90) compared to other diplotypes, while GG/AA showed less hypo-response (19.1% vs 31%, adjOR 0.48, 95% CI 0.24–0.96). This additive diplotype approach confirms that combination genotyping provides better prediction than either SNP alone.

For PCOS susceptibility, a 2017 case-control study of 377 PCOS women and 388 controls⁷⁷ 2017 case-control study of 377 PCOS women and 388 controls
FSH receptor gene p.Thr307Ala and p.Asn680Ser polymorphisms are associated with the risk of PCOS, Journal of Assisted Reproduction and Genetics 2017 found the Ala/Ala genotype had an OR of 2.23 for PCOS (95% CI 1.38–3.68), and confirmed near-complete LD between rs6165 and rs6166 (r²≈99%).

Practical Implications

Because rs6165 and rs6166 are almost always co-inherited, the clinical guidance for rs6165 largely mirrors that for rs6166. Women with the CC genotype at rs6165 (Ala/Ala, the reduced-sensitivity haplotype) should expect a pattern similar to GG carriers at rs6166: potentially reduced oocyte yield at standard FSH doses, compensatory higher basal FSH levels, and the need for dose adjustment in IVF. The critical practical point is that elevated day-3 FSH in these women may reflect receptor sensitivity rather than diminished ovarian reserve⁸⁸ elevated day-3 FSH in these women may reflect receptor sensitivity rather than diminished ovarian reserve
AMH testing, which is not regulated through the FSH receptor, gives a receptor-independent reserve estimate.

Women with the TT genotype (Thr/Thr, carrying the glycosylation site) tend to be more FSH-sensitive, similar to AA carriers at rs6166. An early Indian cohort study found that Ala/Ala women required the lowest FSH doses and had the highest OHSS rate (85%)⁹⁹ Indian cohort study found that Ala/Ala women required the lowest FSH doses and had the highest OHSS rate (85%)
Achrekar et al. Fertility and Sterility 2009, though this study was small and the 85% OHSS figure reflects a highly selected clinical sample.

The Ala307Thr variant adds mechanistic nuance to FSHR pharmacogenetics beyond Asn680Ser: the extracellular glycosylation change likely contributes to FSH binding affinity independently, meaning that haplotype-level information (combining both variants) may refine prediction beyond either SNP alone.

Interactions

rs6166 (FSHR Asn680Ser): The dominant interaction for rs6165. These two variants are in near-complete LD (r²=0.82–0.99, D'=0.997) and form a two-variant haplotype: Ala307-Ser680 (CC + GG, reduced sensitivity) and Thr307-Asn680 (TT + AA, higher sensitivity). Because they are almost never discordant in real genotype data, the clinical guidance is essentially identical. A compound action for the concordant high-risk haplotype (CC at rs6165 + GG at rs6166) is warranted if both SNPs are available in a user's genome file, but would activate for <1% of users who are discordant at the two positions. The rs6166 entry in the hormones-sleep category provides comprehensive IVF dosing guidance for this haplotype.

rs1394205 (FSHR promoter variant): The FSHR promoter polymorphism at rs1394205 (G-29A) operates upstream of both coding variants and influences total receptor expression level independently of receptor sensitivity. A 2024 additive diplotype study¹⁰¹⁰ 2024 additive diplotype study
Reproductive Sciences 2024 found that the rs6165/rs1394205 combination reduced oocyte yield (EMD -1.99, 95% CI -3.57 to -0.42) and FOI (EMD -12.07) in certain diplotype combinations, confirming independent additive effects.

Compound action proposal for rs6165 CC + rs6166 GG (Ala307-Ser680/Ala307-Ser680 homozygous haplotype): Women who are CC at rs6165 AND GG at rs6166 carry the homozygous reduced-sensitivity FSHR haplotype with changes at both the extracellular binding domain (Ala307) and the intracellular signaling domain (Ser680). The combined recommendation would be: request AMH rather than FSH for ovarian reserve assessment; use urinary FSH (uFSH/Menopur) at higher starting doses in IVF; track basal FSH trends as a personal benchmark rather than vs population reference ranges; and discuss the double-variant status with a reproductive endocrinologist before any ovarian stimulation. Evidence level: strong.

Von Willebrand factor (VWF) does two jobs in haemostasis: it captures platelets at sites of vascular injury, and it acts as a molecular chaperone that binds and shields coagulation factor VIII¹¹ factor VIII
the clotting protein deficient in haemophilia A; VWF keeps it from being degraded in the bloodstream before it is needed from premature proteolytic clearance. The rs61748497 variant — encoding the p.Cys1060Arg substitution in the D3 domain — specifically cripples the second job. VWF quantity is normal, platelet plug formation is intact, but FVIII levels fall because the carrier protein can no longer hold its cargo. The result is a condition classified as von Willebrand disease type 2N²² von Willebrand disease type 2N
named for Normandy, France, where the subtype was first described — a bleeding disorder that mimics haemophilia A but arises from a VWF gene defect rather than an FVIII gene defect.

The Mechanism

The VWF gene sits on the minus strand of chromosome 12p13.31. The rs61748497 variant is described as c.3178T>C on the coding strand (NM_000552.5), which corresponds to the plus-strand genomic change NC_000012.12:g.6025624A>G. The substitution converts codon 1060 from TGT (cysteine) to CGT (arginine) — p.Cys1060Arg. Cysteine residues frequently participate in disulphide bonds that maintain tertiary protein structure; the C1060 residue is located in the C8_3 subdomain of the D3 domain, a region critical for the three-dimensional architecture of the VWF-FVIII interaction interface.

Przeradzka et al. (2018)³³ Przeradzka et al. (2018)
Przeradzka MA et al. The D' domain of VWF requires the presence of the D3 domain for optimal factor VIII binding. Biochem J. 2018 used chemical footprinting mass spectrometry to demonstrate that C1060R induces conformational changes in the D3 domain that are quantitatively proportional to the reduction in FVIII binding affinity. The mutation does not simply remove a single contact point — it disrupts the overall fold of the D3 domain in a way that reduces the capacity of the neighbouring D' domain (the canonical FVIII binding site) to engage factor VIII effectively. The result is a FVIII binding capacity that ranges from severely reduced to completely absent depending on whether the patient carries one or two copies of the mutant allele.

The Evidence

The definitive characterization of C1060R comes from Hilbert et al. (2003)⁴⁴ Hilbert et al. (2003)
Hilbert L et al. Two novel mutations, Q1053H and C1060R, located in the D3 domain of VWF, are responsible for decreased FVIII-binding capacity. Br J Haematol. 2003;120(4):627-32, who identified the mutation in seven unrelated French families with type 2N VWD and confirmed its functional impact through site-directed mutagenesis and transient expression in COS-7 cells. C1060R was found in heterozygous, homozygous, and compound heterozygous states, with phenotypic severity tracking the number of mutant alleles. Its occurrence outside the originally described FVIII-binding tryptic fragment (D' domain, residues 764–1035) established that D3 domain integrity is independently required for FVIII binding.

The index description of a clinically important compound heterozygous case appears in Mazurier et al. (2002)⁵⁵ Mazurier et al. (2002)
Mazurier C et al. Factor VIII deficiency not induced by FVIII gene mutation in a female first cousin of two brothers with haemophilia A. Br J Haematol. 2002;119(2):390-2: a 20-year-old woman with reduced FVIII activity was initially thought to be an obligate carrier of the family's haemophilia A mutation. She was instead found to carry compound heterozygosity for Y357X (a VWF null allele, rs61754002) and C1060R. Her VWF antigen levels were very low due to the null allele, her VWF:FVIII binding was undetectable, and her FVIII activity was severely reduced — a phenotype indistinguishable from haemophilia A on conventional testing. This case illustrates the diagnostic trap: any female presenting with isolated FVIII deficiency should have VWF molecular testing before haemophilia A carrier status is assumed.

The 2021 ASH/ISTH/NHF/WFH diagnostic guidelines⁶⁶ 2021 ASH/ISTH/NHF/WFH diagnostic guidelines
James PD et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD. Blood Adv. 2021;5(1):280-300 specifically include a diagnostic algorithm for type 2N: low FVIII with normal or borderline VWF antigen and ristocetin cofactor activity is the laboratory signature. Confirmation requires a VWF:FVIII binding assay — a test that directly measures VWF's capacity to bind factor VIII at physiological conditions. Genetic testing (sequencing of VWF exons encoding the D' and D3 domains) is recommended alongside phenotypic assays because heterozygous carriers can present with borderline laboratory values, and accurate diagnosis is essential for correct treatment.

Practical Actions

The critical clinical point is that desmopressin (DDAVP) does not correct the type 2N defect. Desmopressin releases stored VWF from endothelial cells, temporarily raising VWF antigen and — secondarily — FVIII levels. But the released VWF still carries the C1060R mutation and cannot bind FVIII normally: within hours, FVIII levels fall back as unprotected factor VIII is cleared from circulation. For haemostasis in type 2N patients, only VWF/FVIII concentrate (which delivers functional FVIII directly alongside VWF) reliably restores haemostatic competence. The 2021 management guidelines⁷⁷ 2021 management guidelines
Connell NT et al. ASH ISTH NHF WFH 2021 guidelines on the management of VWD. Blood Adv. 2021;5(1):301-325 recommend VWF/FVIII concentrate as the treatment of choice for type 2N, targeting VWF activity and FVIII activity ≥0.50 IU/mL peri-operatively.

Heterozygous carriers may or may not have measurable clinical phenotypes, depending on FVIII levels. Some carriers have FVIII in the low-normal range (40–60 IU/dL) and are entirely asymptomatic; others fall below normal thresholds and have mild bleeding symptoms, particularly around surgery or childbirth.

Interactions

C1060R is most clinically significant in compound heterozygous combination with a VWF null allele — where one allele produces no VWF protein and the other produces VWF that cannot bind FVIII. The index case (Mazurier 2002) carried C1060R together with Y357X (rs61754002), a nonsense allele that produces no VWF at all. In that combination, VWF antigen is reduced (driven by the null allele), VWF:FVIII binding is abolished (driven by C1060R), and FVIII activity is critically low — a full phenotypic haemophilia A presentation in a VWF gene carrier. Any VWF null allele (type 3 disease allele) on the second chromosome would produce a similar compound effect.

Blood group O independently lowers VWF antigen by 15–25%, which may push a heterozygous C1060R carrier's effective FVIII levels further below the normal range and worsen clinical bleeding phenotype without affecting the molecular defect.

Sex hormone-binding globulin is the liver's principal carrier for testosterone and estradiol. Only a tiny fraction of circulating testosterone — roughly 1–3% — is truly free and biologically active; SHBG tightly binds the rest, holding it in reserve. Rs6259 changes one amino acid deep in SHBG's C-terminal domain, and the consequence is biochemically elegant: the substitution creates a new site where sugar chains can attach to the protein. That extra glycosylation extends SHBG's survival in the bloodstream, pushing circulating SHBG concentrations higher — and shifting the balance between bound and free sex hormones.

The Mechanism

The variant converts aspartate to asparagine at position 356 of the SHBG precursor protein (position 327 in the older mature-protein numbering, giving rise to the historically common "Asp327Asn" or "D327N" designation in older literature). Asparagine at this position creates an [N-linked glycosylation consensus sequence | The sequence motif Asn-X-Ser/Thr, where X is any amino acid except proline, is recognized by the oligosaccharyltransferase complex in the endoplasmic reticulum as a site for N-linked sugar chain attachment] that the wild-type aspartate does not support.

A key nuance: [biochemical studies of SHBG glycosylation | Bocchinfuso et al. Endocrinology 1992, PMID 1425432; Hammond & Bocchinfuso J Steroid Biochem Mol Biol 1995, PMID 7626508] show that N-linked carbohydrate chains do NOT alter SHBG's steroid-binding affinity for testosterone or dihydrotestosterone. The extra glycosylation does not make SHBG bind more or less tightly to testosterone at the steroid-binding pocket (located in the N-terminal domain). Instead, the primary effect is on SHBG's metabolic fate: the additional sugar chain is thought to [increase protein half-life | by masking protease cleavage sites and modulating hepatic clearance receptors; the C-terminal domain containing this glycosylation site is also involved in SHBG's membrane receptor interactions] in the bloodstream, resulting in higher steady-state SHBG concentrations. Higher total SHBG means more testosterone is bound — reducing free androgen availability even though each SHBG molecule binds testosterone with unchanged affinity.

There is also a haplotype-level interaction: the [Thompson 2008 haplotype analysis | Thompson et al. Cancer Epidemiol Biomarkers Prev 2008, PMID 19064566] of 11 SHBG SNPs found that the rs6259 A allele (D356N) specifically neutralizes the SHBG-lowering effect of the rs858518/ rs727428 haplotype. When D356N is present on the same chromosomal background as the otherwise SHBG-lowering haplotype, the expected drop in SHBG does not occur — making rs6259 a key modifier of other SHBG variants' effects.

The Evidence

The clearest quantitative evidence comes from a 2009 study of men across three age groups¹¹ 2009 study of men across three age groups
Vanbillemont et al. Clin Endocrinol (Oxf) 2009, PMID 18681858, which found that A allele carriers in the middle-aged cohort had 14.2% higher SHBG (P<0.001) and 7.3% higher total testosterone (P=0.01) compared to GG homozygotes, with no significant change in free testosterone — consistent with the body maintaining free testosterone homeostasis through LH feedback while total SHBG rises.

A 2025 sibling study of 999 Dutch men²² 2025 sibling study of 999 Dutch men
Walravens et al. J Clin Endocrinol Metab 2025, PMID 38652149 confirmed that rs6259 A allele carriers showed higher SHBG and total testosterone with no clear effect on measured free testosterone. In the Dunning 2004 study of postmenopausal women³³ Dunning 2004 study of postmenopausal women
JNCI 2004, PMID 15199113, D356N was significantly associated with circulating SHBG levels (P=0.005) and the estradiol-to-SHBG ratio (P=0.01), explaining 0.6% of SHBG variance.

In the context of PCOS and metabolic syndrome, higher SHBG from the A allele appears protective. A Chinese Han male study (n=384)⁴⁴ Chinese Han male study (n=384)
Pang et al. Aging Clin Exp Res 2014, PMID 24671943 found A allele carriers had significantly lower metabolic syndrome risk (OR 0.56, 95% CI 0.33–0.96) alongside higher SHBG. A meta-analysis of 4,733 participants⁵⁵ meta-analysis of 4,733 participants
Li et al. Reprod Biomed Online 2021, PMID 33168491 found rs6259 was not significantly associated with PCOS risk overall — consistent with the larger Liao & Cao 2020 meta-analysis (1,660 PCOS cases, 1,312 controls, PMID 32589470) that also found no significant PCOS association. The mechanistic expectation (higher SHBG → lower free androgen index → protective against PCOS) is biologically plausible, but the genetic signal is not robust across all populations.

For breast cancer, a meta-analysis of 10,454 cases and 13,111 controls⁶⁶ meta-analysis of 10,454 cases and 13,111 controls
Zhou et al. Mol Biol Rep 2012, PMID 22711300 found no significant overall association with the Asp356Asn variant, but a protective effect emerged specifically in postmenopausal Asian women (dominant model OR 0.83, 95% CI 0.70–0.97). A Shanghai population-based study (1,106 cases, 1,180 controls) confirmed this pattern⁷⁷ confirmed this pattern
Cui et al. Cancer Epidemiol Biomarkers Prev 2005, PMID 15894658, finding OR 0.73 (95% CI 0.53–0.99) in postmenopausal women, with the strongest protection in lean women (OR 0.46) — consistent with the A allele raising SHBG, thereby sequestering more estradiol in the lower-estrogen postmenopausal environment.

An unexpected finding comes from prostate cancer: a Japanese study of 70 men on androgen deprivation therapy⁸⁸ Japanese study of 70 men on androgen deprivation therapy
Shiota et al. Clin Genitourin Cancer 2019, PMID 31036465 found that A allele carriers had dramatically worse outcomes, with HR 2.20 for progression (P=0.027) and HR 3.21 for mortality (P=0.012), despite comparable testosterone suppression across genotypes. The mechanism remains under investigation — one hypothesis is that higher SHBG levels in A allele carriers paradoxically maintain a reservoir of bioavailable androgen through SHBG membrane receptor-mediated signaling, which may fuel castration-resistant prostate cancer progression through non-classical androgen pathways.

For bone health, a study of postmenopausal women⁹⁹ study of postmenopausal women
Napoli et al. Bone 2009, PMID 19679209 found that A allele carriers had significantly lower bone mineral density at the total femur (P=0.004) and intertrochanter (P=0.002), without detectable differences in free estradiol — suggesting the skeletal effect may be mediated through SHBG's membrane receptor signaling or other estrogen-independent mechanisms.

Practical Implications

For most people, rs6259 GG genotype is the common variant (approximately 79% globally). A allele carriers — particularly AA homozygotes, who are rare (~1% of the population) — have measurably higher SHBG and a distinct hormone profile. The practical implications are most relevant for: (1) interpreting sex hormone panels (higher SHBG inflates total testosterone while free testosterone may be maintained); (2) prostate cancer treatment planning, where genotype may influence ADT response; and (3) breast cancer risk stratification in postmenopausal Asian women.

Interactions

rs727428 and rs858518 (SHBG regulatory variants): The Thompson 2008 haplotype analysis showed that rs6259 D356N neutralizes the SHBG-lowering haplotype formed by rs858518 and rs727428. A person carrying the A allele at rs6259 alongside the T allele at rs727428 or the A allele at rs858518 will partially or fully offset the expected SHBG reduction from those regulatory variants. This is relevant for anyone carrying risk genotypes at multiple SHBG loci — the net SHBG effect is the sum of all contributing variants, with rs6259 A acting as a counterweight to the rs727428/rs858518 lowering effect.

rs1799941 (SHBG promoter G-68A): This promoter variant in the hormones-sleep category also regulates SHBG levels through expression changes. Carriers of both rs1799941 A allele (higher SHBG) and rs6259 A allele (higher SHBG) would have additive SHBG-raising effects. For PCOS risk assessment and prostate cancer ADT planning, total SHBG genotype burden across all four SHBG variants (rs727428, rs858518, rs1799941, rs6259) provides the most informative picture.

Proposed interaction for supervisor review: Men with GA or AA genotype at rs6259 who are considering or undergoing androgen deprivation therapy for prostate cancer should have rs6259 genotype documented alongside baseline SHBG levels, as the Shiota 2019 data suggest this may be an independent prognostic factor for ADT response regardless of testosterone suppression depth.